Targeting the RANKL pathway: Putting the brakes on prostate cancer progression in bone

Journal of Clinical Oncology

Volumn 31, Issue 30, 2013, Pages 3838-3840

  Garraway, Isla P ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BONE DISEASE; BONE METASTASIS; CANCER GROWTH; CANCER PREVENTION; CANCER REGRESSION; CASTRATION RESISTANT PROSTATE CANCER; ENZYME INHIBITION; HUMAN; INTRACELLULAR SIGNALING; METASTASIS FREE SURVIVAL; OSTEOCLAST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; AGED; BLOOD; BONE TUMOR; DISEASE COURSE; DRUG EFFECTS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; SECONDARY; SIGNAL TRANSDUCTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; OSTEOCLASTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 84891518980     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.1544     Document Type: Article

References (33)

1. Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s-6249s, 2006
2. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial-The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 79:235-246, 1997
3. Smith MR, Kabbinavar F, Saad F, et al: Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23:2918-2925, 2005
4. Paller CJ, Carducci MA, Philips GK: Management of bone metastases in refractory prostate cancer: Role of denosumab. Clin Interv Aging 7:363-372, 2012
5. Rove KO, Crawford ED: Evolution of treatment options for patients with CRPC and bone metastases: Bone-targeted agents that go beyond palliation of symptoms to improve overall survival. Oncology (Williston Park) 25:1362-1370, 1375-1381, 1387, 2011
6. Smith MR, Saad F, Coleman R, et al: Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial. Lancet 379:39-46, 2012
7. Fizazi K, Carducci M, Smith M, et al: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 377:813-822, 2011
8. Saad F, Gleason DM, Murray R, et al: Longterm efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882, 2004
9. Smith MR, Saad F, Oudard S, et al: Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: Exploratory analyses by baseline prostatespecific antigen doubling time. J Clin Oncol 31:3800-3806, 2013
10. D'Amico AV, Moul JW, Carroll PR, et al: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376-1383, 2003
11. Reid IR: Anti-resorptive therapies for osteoporosis. Semin Cell Dev Biol 19:473-478, 2008
12. Murthy RK, Morrow PK, Theriault RL: Bone biology and the role of the RANK ligand pathway. Oncology (Williston Park) 23:9-15, 2009 (suppl 5)
13. Anderson DM, Maraskovsky E, Billingsley WL, et al: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179, 1997
14. Boyce BF, Xing L: Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 9:S1, 2007 (suppl 1)
15. Teitelbaum SL, Ross FP: Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-649, 2003
16. Kapur RP, Yao Z, Iida MH, et al: Malignant autosomal recessive osteopetrosis caused by spontaneous mutation of murine Rank. J Bone Miner Res 19:1689-1697, 2004
17. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490-495, 2004
18. Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997
19. Chung JY, Lu M, Yin Q, et al: All TRAFs are not created equal: Common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 115:679-688, 2002
20. Darnay BG, Besse A, Poblenz AT, et al: TRAFs in RANK signaling. Adv Exp Med Biol 597:152-159, 2007
21. Takayanagi H, Kim S, Koga T, et al: Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889-901, 2002
22. Karsenty G, Wagner EF: Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2:389-406, 2002
23. Feller L, Kramer B, Lemmer J: A short account of metastatic bone disease. Cancer Cell Int 11:24, 2011
24. Loberg RD, Gayed BA, Olson KB, et al: A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. J Cell Biochem 96:439-446, 2005
25. Loriot Y, Massard C, Fizazi K: Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. Ann Oncol 23: 1085-1094, 2012
26. Guise TA, Mohammad KS, Clines G, et al: Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12: 6213s-6216s, 2006
27. Brown JE, Neville-Webbe H, Coleman RE: The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 11:207-224, 2004
28. Drake MT, Clarke BL, Khosla S: Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032-1045, 2008
29. Saad F, Eastham J: Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology 76:1175-1181, 2010
30. Saad F, Lipton A: Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 34:S17-S23, 2007 (suppl 4)
31. Kostenuik PJ, Nguyen HQ, McCabe J, et al: Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 24:182-195, 2009
32. Seeman E, Delmas PD, Hanley DA, et al: Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate. J Bone Miner Res 25:1886-1894, 2010
33. Saylor PJ, Armstrong AJ, Fizazi K, et al: New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 63:309-320, 2013